|
MechanismIL-17RA antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date04 Jul 2016 |
Target- |
MechanismPhotosensitizers |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CH |
First Approval Date09 Apr 2000 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date29 Dec 1999 |
100 Clinical Results associated with Valeant Pharmaceuticals Luxembourg S.à r.l.
0 Patents (Medical) associated with Valeant Pharmaceuticals Luxembourg S.à r.l.
100 Deals associated with Valeant Pharmaceuticals Luxembourg S.à r.l.
100 Translational Medicine associated with Valeant Pharmaceuticals Luxembourg S.à r.l.